# US 2024/0255509 A1 · Compositions and methods related to k180 dimethylated h1.0 protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0255509 A1
- Document ID: US20240255509A1
- Status: Published application
- Kind: A1
- Application number: 18/506,086
- Filed: 2023-11-09
- Published: 2024-08-01
- Earliest claimed: 2016-04-20
- Assignees: Aelan Cell Technologies, Inc.
- Applicants: Aelan Cell Technologies, Inc.
- Inventors: Victoria LUNYAK; James Robert TOLLERVEY
- Web page: https://patentgrep.com/patent/US20240255509A1

## CPC

- G01N 33/573: for enzymes or isoenzymes
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/47: from mammals
- C07K 16/18: against material from animals or humans
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C12N 9/1007: {Methyltransferases (general) (2.1.1.)}
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C12P 21/06: produced by the hydrolysis of a peptide bond, e.g. hydrolysate products (preparing foodstuffs by protein hydrolysis A23J3/00)
- C12Y 201/01043: Histone-lysine N-methyltransferase (2.1.1.43)
- G01N 33/54306: {Solid-phase reaction mechanisms}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- C12Y 201/01: Methyltransferases (2.1.1)
- G01N 2800/2821: Alzheimer
- G01N 2800/50: Determining the risk of developing a disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES

## Abstract

Provided herein are H1.0K180me2 antibodies, H1.0K180me2 proteins, and H1.0K180me2 peptides and methods of use for diagnostics and therapeutics. These H1.0K180me2 antibodies, H1.0K180me2 proteins, and H1.0K180me2 peptides may be used in the treatment of methylated H1.0-related diseases or conditions in an individual. These H1.0K180me2 antibodies, H1.0K180me2 proteins, and H1.0K180me2 peptides may also be used for the detection and quantification of a histone H1.0 protein or fragment thereof, comprising a dimethylated lysine at lysine residue 180 (H1.0K180me2); such compositions and methods are useful for detecting replicative senescence, DNA damage, genotoxic stress, radiation exposure, Alzheimer's disease, are useful for monitoring therapeutic regimens, patient stratification, drug screening, and may serve as a marker of biological aging in a system.

## Claims

### Claim at position 1

-15. (canceled)

### Claim 16

A synthetic histone H1.0 peptide comprising a dimethylated lysine residue, wherein the dimethylated lysine residue corresponds to K180 of a human histone H1.0.

### Claim 17 (depends on 16)

The peptide of claim 16, wherein the peptide comprises a label.

### Claim 18 (depends on 16)

The peptide of claim 16, wherein the peptide is biotinylated.

### Claim 19 (depends on 16)

The peptide of claim 16, wherein the peptide does not comprise any other lysine residues that are dimethylated.

### Claim at position 6

-21. (canceled)

### Claim 22 (depends on 16)

The peptide of claim 16, wherein the peptide comprises any one of the sequences of SEQ ID NOS:3-35.

### Claim at position 8

-25. (canceled)

### Claim 26 (depends on 16)

The peptide of claim 16, wherein the peptide is capable of clearing or blocking H1.0K180me2 autoantibodies.

### Claim at position 10

-182. (canceled)

### Claim 183 (depends on 16)

The peptide of claim 16, wherein the peptide has a length of between 5 amino acids and 30 amino acids.

### Claim 184 (depends on 22)

The peptide of claim 22, wherein the peptide consists of a sequence selected from the group consisting of SEQ ID NOS:3-35.

### Claim 185 (depends on 16)

The peptide of claim 16, wherein the peptide is attached to a bead, microplate, column, or resin.

### Claim 186 (depends on 16)

The peptide of claim 16, wherein the peptide is conjugated to at least one therapeutic agent selected from the group consisting of a radionuclide, a cytotoxin, a chemotherapeutic agent, a drug, a pro-drug, a toxin, an enzyme, an immunomodulator, a pro-apoptotic agent, a cytokine, a hormone, an oligonucleotide, an antisense molecule, a siRNA, and a second antibody.

### Claim 187 (depends on 26)

The peptide of claim 26, wherein the H1.0K180me2 autoantibodies comprise IgG antibodies, IgG antibodies, or a combination thereof.

### Claim 188 (depends on 1)

A diagnostic kit comprising the peptide of claim 1.

### Claim 189 (depends on 188)

The kit of claim 188, wherein the peptide is provided as a reference standard.

### Claim 190 (depends on 188)

The kit of claim 188, wherein the kit further comprises an anti-H1.0K180me2 antibody.

### Claim 191 (depends on 1)

A transdermal patch for measuring a concentration of a hypodermal target molecule, comprising:
(a) a substrate comprising the peptide of claim 1; and
(b) a plurality of microneedles.

### Claim 192 (depends on 191)

The patch of claim 191, wherein the patch is configured as a transdermal microneedle array patch.

### Claim 193 (depends on 191)

The patch of claim 191, wherein the substrate is elastically stretchable.

### Claim 194 (depends on 1)

A portable unit for determining whether an individual has been exposed to radiation or a DNA-damaging agent, comprising:
(a) a sample collection unit;
(b) a reader;
(c) an assay module comprising the peptide of claim 1; and
(d) a plurality of microneedles.

### Claim 195 (depends on 1)

A test strip suitable for a lateral flow assay of an analyte, comprising a sample receiving zone, wherein the sample receiving zone comprises the peptide of claim 1.

### Claim 196 (depends on 1)

A pharmaceutical composition comprising the peptide of claim 1 and a pharmaceutically acceptable excipient.
